These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 36971375)
1. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review. Rodriguez R; Kaluzna SD Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375 [TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials. Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304 [TBL] [Abstract][Full Text] [Related]
4. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550 [TBL] [Abstract][Full Text] [Related]
5. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure. Chen K; Nie Z; Shi R; Yu D; Wang Q; Shao F; Wu G; Wu Z; Chen T; Li C JAMA Netw Open; 2023 Aug; 6(8):e2330754. PubMed ID: 37615988 [TBL] [Abstract][Full Text] [Related]
7. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Starr JA; Pinner NA; Lisenby KM; Osmonson A Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578 [TBL] [Abstract][Full Text] [Related]
8. Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death? Mukhopadhyay P; Sanyal D; Chatterjee P; Pandit K; Ghosh S Endocr Pract; 2022 Aug; 28(8):795-801. PubMed ID: 35569736 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480 [TBL] [Abstract][Full Text] [Related]
10. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169 [TBL] [Abstract][Full Text] [Related]
12. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392 [TBL] [Abstract][Full Text] [Related]
14. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
15. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE. Packer M; Butler J Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655 [TBL] [Abstract][Full Text] [Related]
16. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Long A; Salvo M Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844 [TBL] [Abstract][Full Text] [Related]
17. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Starr JA; Pinner NA Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422 [TBL] [Abstract][Full Text] [Related]
18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Aguilar-Gallardo JS; Correa A; Contreras JP Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341 [TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. Chen HB; Yang YL; Meng RS; Liu XW ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979 [TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]